Hope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
About This Group of Stocks
Our Expert Thinking
This portfolio focuses on companies pursuing world-altering innovations with enormous growth potential. We've identified pioneers in gene editing, advanced nuclear, carbon capture, and other cutting-edge fields poised to transform industries while addressing critical global challenges.
What You Need to Know
These investments represent high-risk, high-reward opportunities with significant volatility. They're best suited for forward-looking investors comfortable with uncertainty in exchange for potential outsized returns. Consider these stocks as satellite holdings in a diversified portfolio.
Why These Stocks
Each company was selected for its robust intellectual property, clear market disruption potential, and position at the forefront of scientific or technological frontiers. Current tailwinds include accelerated regulatory pathways and increased global investment in biotechnology and clean energy infrastructure.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+656.79%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 656.79% over the next year.
Stocks Rated Buy by Analysts
11 of 14 assets in this group are rated Buy by professional analysts.
Group Growth vs Bank interest
This group averaged a 443.9% return last month, beating the typical 4% bank rate.
Why You'll Want to Watch These Stocks
Breakthrough Moments Ahead
These companies are at critical development milestones. Clinical trial results, regulatory decisions, and technology demonstrations could trigger significant price movements in the coming months.
The Future-Makers Club
While others talk about changing the world, these companies are actually building the technologies to make it happen. Being early in transformative innovation has historically created exceptional wealth opportunities.
Innovation's Hidden Champions
Many of these pioneers fly under the radar of mainstream investors despite their revolutionary potential. Their breakthroughs in gene editing and clean energy could reshape entire industries before most people notice.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Pharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Frequently Asked Questions
Everything you need to know about the product and billing.